pyrazines has been researched along with orlistat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garg, R; Hussey, C; Ibrahim, S | 1 |
| Cózar-Castellano, I; Joumady, I; Perdomo, G; Sáez-Benito, A; Tirado-Vélez, JM | 1 |
2 other study(ies) available for pyrazines and orlistat
| Article | Year |
|---|---|
Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report.
Topics: Anti-Obesity Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Lactones; Middle Aged; Orlistat; Pancreatitis; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Carbohydrate Metabolism; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerulenin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Epoxy Compounds; Fatty Acids; G1 Phase Cell Cycle Checkpoints; Glucose; Humans; Lactones; Lipid Metabolism; Multiple Myeloma; Orlistat; Oxidation-Reduction; Pyrazines; Retinoblastoma Protein | 2012 |